@article{TCR30152,
author = {Navid Djassemi and Shilpa Rampey and Juhi Motiani},
title = {Examining the evolving utility of 18FDG-PET/CT in breast cancer recurrence},
journal = {Translational Cancer Research},
volume = {9},
number = {Suppl 1},
year = {2019},
keywords = {},
abstract = {Many studies have demonstrated the utility of 18fluorodeoxyglucose-positron emission tomography/computed tomography (18FDG-PET/CT) scan in evaluating breast cancer recurrence in subsets of patients based on age, histological subtype and cancer stage to guide response to conventional chemoradiation guidelines during treatment of metastatic breast cancer disease. This literature review focuses on the breakthrough of 18FDG-PET/CT imaging within the paradigm of breast cancer oncology centered toward improving risk stratification and prognostication of disease relapse based on cancer molecular phenotypes, tumor markers, early metabolic activity and response to neoadjuvant chemotherapy (NAC). The authors consider the rapid shift toward biomarker based molecular tracers to quantify treatment response and pathologic complete response with more recent imaging modalities such as dedicated breast positron emission tomography (dbPET), and the advantages afforded by this multisystem approach.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/30152}
}